← Back to Search

Diagnostic Test

MRI for Salivary Gland Tumors (PSGT Trial)

N/A

Recruiting

Led By Sanjeev Chawla

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Possess a salivary gland lesion of 1cm3 size

Have no prior history of treatment for salivary gland lesion

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 month after the end of treatment

Awards & highlights

PSGT Trial Summary

This trial uses MRI to compare cancerous and non-cancerous salivary gland tumors in hopes of better treatment strategies and predictions of disease progression.

Who is the study for?

This clinical trial is for individuals with salivary gland lesions at least 1cm3 in size, who haven't had any treatment for these lesions before. It's not suitable for pregnant individuals, those with a history of cancer (other than salivary gland tumors), people with conditions that make MRI unsafe, kidney disease patients, or anyone who has received radiation therapy to the head and neck.Check my eligibility

What is being tested?

The study is testing advanced MRI techniques to distinguish between benign (non-cancerous) and malignant (cancerous) salivary gland tumors. The aim is to improve treatment decisions and predict how the disease may progress over time.See study design

What are the potential side effects?

MRI does not involve radiation and generally has no side effects. However, some people might experience discomfort from lying still during the procedure or feel claustrophobic inside the MRI machine.

PSGT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a salivary gland lesion that is at least 1cm3 in size.

Select...

I have never been treated for a salivary gland issue.

PSGT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 month after the end of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 month after the end of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 month after the end of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Differentiation and Progression Free

PSGT Trial Design

1Treatment groups

Experimental Treatment

Group I: Salivary Gland TumorExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MRI

2009

Completed Phase 2

~1370

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor

2,002 Previous Clinical Trials

42,880,839 Total Patients Enrolled

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

104,904 Total Patients Enrolled

McCabe FundUNKNOWN

Media Library

MRI (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04452162 — N/A

Salivary Gland Tumors Research Study Groups: Salivary Gland Tumor

Salivary Gland Tumors Clinical Trial 2023: MRI Highlights & Side Effects. Trial Name: NCT04452162 — N/A

MRI (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04452162 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available positions for new test subjects?

"Yes, this is an ongoing trial, which was first announced on August 25th, 2020 and has since been updated on June 19th, 2022 according to clinicaltrials.gov."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Physiologic MR Imaging of Salivary Gland Tumors

Sanjeev Chawla 2020. "Physiologic MR Imaging of Salivary Gland Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04452162.